@FierceBiotech: Biogen's hemophilia hopeful scores a PhIII win as FDA awaits. News | Follow @FierceBiotech
@JohnCFierce: Celladon's heart drug grabs 'breakthrough' status at FDA. Item | Follow @JohnCFierce
@DamianFierce: As $GILD gets pilloried over pricing, $BMY (Article) and $MRK (Story) creep up in hep C. | Follow @DamianFierce
@EmilyMFierce: WHO offers road map for new vaccine introduction. Article | Follow @EmilyMFierce
> Sofinnova Ventures led a $57 million Series B round for Edinburgh, Scotland-based NuCana, which is developing a pipeline of new cancer drugs. Release (PDF)
> A new government measure in France allowing physicians to substitute branded biologics with cheaper biosimilars coming into the market is causing some alarm in biopharma circles. Some observers say others in the EU may follow suit, threatening older products from the likes of Amgen ($AMGN) and Roche ($RHHBY). Story
> The troubled Cambridge, MA-based Aveo ($AVEO) has lined up a partner for its development work. The diagnostics company Biodesix has agreed to provide $15 million to help fund a study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected with its VeriStrat test. Release
> Northwest Biotherapeutics says it has grabbed a funding commitment from an unnamed investor for up to $32 million. Release
@FierceMedDev: Boston Scientific eyes Israel in global marketing push. News | Follow @FierceMedDev
@VarunSaxena2: ICYMI: Adaptive Biotechnologies raises $120M to bolster its immune Dx. Article | Follow @VarunSaxena2
@EmilyWFierce: U.S. and European docs want to put the kibosh on renal denervation devices. Story | Follow @EmilyWFierce
@MichaelGFierce: ICYMI from FierceDrugDelivery: Nanoballoons 'pop' open to deliver cancer drugs when hit with a red laser. Story | Follow @MichaelGFierce
> Abbott creeps toward the FDA with its dissolvable stent. More
> Tendyne raises $25M in Series C financing for mitral valve device. Article
Pharma News
@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma
@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton
@EricPFierce: Sources tell Economic Times that Sun will phase out Ranbaxy brand in U.S. Sun doesn't deny it. More | Follow @EricPFierce
@CarlyHFierce: Hamburg to pharma at PhRMA 14, on improving applications: "One message, and I maybe will come to regret it, is really do reach out and engage with us." | Follow @CarlyHFierce
> Cochrane study: Stockpiling Tamiflu, Relenza was $2B 'thrown down the drain.' Story
> Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit. More
> Hospira wins Herceptin patent suit in U.K., paving way for biosim. Article
> French watchdogs raid Novartis, Roche in Lucentis antitrust probe. News
Pharma Manufacturing News
> Neuland opens API plant as part of its partnership with Mitsubishi. More
> Kyowa Hakko Kirin finishes $60M biologics API plant. Story
> Sources: Sun has blueprint for turning Ranbaxy around. Article
> AbbVie partners with Arabio for production in Saudi Arabia. More
> Novartis' government-backed vaccine plant should be operational by 2017. Item
Vaccines News
> Merck KGaA lung cancer vaccine gets a second shot with start of PhIII trial. Story
> Colorado Senate hears vaccine bill testimony. Item
> Report: Emergency flu vaccine manufacturing site will be online by 2017. Article
> Novartis' Bexsero wins FDA 'breakthrough' status. More